Literature DB >> 23442856

Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Michela De Bellis1, Annamaria De Luca, Jean F Desaphy, Roberta Carbonara, Judith A Heiny, Ann Kennedy, Alessia Carocci, Maria M Cavalluzzi, Giovanni Lentini, Carlo Franchini, Diana Conte Camerino.   

Abstract

Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the rational design of new Na(v)-channel blockers. The effects of the novel analogs were tested on sodium currents of native myofibers. Data and molecular modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block. This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance between positive charge and aromatic ring (Me13) or with homologs having the chirality center nearby the amino group or the aromatic ring. Accordingly, a phenyl group on the asymmetric center in the homologated alkyl chain (Me12), leads to a further increase of use-dependent behavior versus the phenyl Mex derivative Me4. A fluorine atom in paraposition and one ortho-methyl group on the xylyloxy ring (Me15) increase potency and stereoselectivity versus Me4. Charge delocalization and greater flexibility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the binding site. Me12 and Me15 show limited selectivity against Na(v)-isoforms, possibly due to the highly conserved binding site on Na(v). To our knowledge, the new compounds are the most potent Mex-like Na(v) blockers obtained to date and deserve further investigation.
Copyright © 2013 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23442856      PMCID: PMC3552273          DOI: 10.1016/j.bpj.2012.11.3830

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  39 in total

1.  Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine.

Authors:  Jean-François Desaphy; Antonella Dipalma; Michela De Bellis; Teresa Costanza; Christelle Gaudioso; Patrick Delmas; Alfred L George; Diana Conte Camerino
Journal:  Pain       Date:  2009-02-12       Impact factor: 6.961

2.  A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel.

Authors:  H L Li; A Galue; L Meadows; D S Ragsdale
Journal:  Mol Pharmacol       Date:  1999-01       Impact factor: 4.436

Review 3.  Sodium channel molecular conformations and antiarrhythmic drug affinity.

Authors:  Michael F Sheets; Harry A Fozzard; Gregory M Lipkind; Dorothy A Hanck
Journal:  Trends Cardiovasc Med       Date:  2010-01       Impact factor: 6.677

4.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

Authors:  S Talon; A De Luca; M De Bellis; J F Desaphy; G Lentini; A Scilimati; F Corbo; C Franchini; P Tortorella; H Jockusch; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Point mutations at L1280 in Nav1.4 channel D3-S6 modulate binding affinity and stereoselectivity of bupivacaine enantiomers.

Authors:  Carla Nau; Sho-Ya Wang; Ging Kuo Wang
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

6.  Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.

Authors:  Alessia Carocci; Alessia Catalano; Claudio Bruno; Giovanni Lentini; Carlo Franchini; Michela De Bellis; Annamaria De Luca; Diana Conte Camerino
Journal:  Chirality       Date:  2010-03       Impact factor: 2.437

7.  2D- and 3D-QSAR of tocainide and mexiletine analogues acting as Na(v)1.4 channel blockers.

Authors:  Antonio Carrieri; Marilena Muraglia; Filomena Corbo; Concetta Pacifico
Journal:  Eur J Med Chem       Date:  2008-10-14       Impact factor: 6.514

8.  New antiarrhythmic agents. 3. Primary beta-amino anilides.

Authors:  P A Tenthorey; R L DiRubio; H S Feldman; B H Takman; E W Byrnes; P D McMaster
Journal:  J Med Chem       Date:  1979-10       Impact factor: 7.446

9.  The crystal structure of a voltage-gated sodium channel.

Authors:  Jian Payandeh; Todd Scheuer; Ning Zheng; William A Catterall
Journal:  Nature       Date:  2011-07-10       Impact factor: 49.962

10.  Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers.

Authors:  A De Luca; F Natuzzi; G Lentini; C Franchini; V Tortorella; D Conte Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

View more
  5 in total

1.  Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.

Authors:  Gualtiero Milani; Maria Maddalena Cavalluzzi; Concetta Altamura; Antonella Santoro; Mariagrazia Perrone; Marilena Muraglia; Nicola Antonio Colabufo; Filomena Corbo; Elisabetta Casalino; Carlo Franchini; Isabella Pisano; Jean-François Desaphy; Antonio Carrieri; Alessia Carocci; Giovanni Lentini
Journal:  ChemMedChem       Date:  2021-10-05       Impact factor: 3.540

2.  Toward precision medicine in myotonic syndromes.

Authors:  Michela De Bellis; Diana Conte Camerino; Jean-François Desaphy
Journal:  Oncotarget       Date:  2017-02-28

Review 3.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Authors:  Paola Imbrici; Antonella Liantonio; Giulia M Camerino; Michela De Bellis; Claudia Camerino; Antonietta Mele; Arcangela Giustino; Sabata Pierno; Annamaria De Luca; Domenico Tricarico; Jean-Francois Desaphy; Diana Conte
Journal:  Front Pharmacol       Date:  2016-05-10       Impact factor: 5.810

4.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

5.  Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.

Authors:  Michela De Bellis; Francesca Sanarica; Alessia Carocci; Giovanni Lentini; Sabata Pierno; Jean-François Rolland; Diana Conte Camerino; Annamaria De Luca
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.